EC Number |
Inhibitors |
Structure |
---|
2.7.12.2 | more |
inactivated by the serine/threonine phosphatase 2A but not by the protein-tyrosine phosphatase 1B |
|
2.7.12.2 | more |
occludin acts as antagonist of the MEK and ERK signaling pathway inducing cell aggregation of pancreatic cancer cells |
|
2.7.12.2 | more |
treatment with LY294002, paclitaxel, or serum starvation does not induce apoptosis of wild-type MEF cells |
|
2.7.12.2 | more |
design and synthesis of 4-anilino-5-carboxamido-2-pyridone MEK1 inhibitors using a combination of medicinal chemistry, computational chemistry, and structural elucidation, overview. Binding structure analysis, overview |
|
2.7.12.2 | more |
no MEK inhibition by theobromine |
|
2.7.12.2 | more |
MEK, p38, and IKK inhibitors block TNF-alpha-induced IL-8, IL-6, and GM-CSF secretion and 12z invasion, whereas the PI3K inhibitors do not |
|
2.7.12.2 | more |
stress-induced target of rapamycin complex 1 activation can be blocked by RNAi against mitogen-activated protein kinase kinase 3 and 6 |
|
2.7.12.2 | more |
known inhibitor structure screening, and design of specific allosteric MEK1/2 inhibitors with improved pharmacokinetic/pharmacodynamic profiles to be used as alternative cancer medications. Trametinib is used as the lead structure. Molecular docking and binding simulations, thermodynamics, and quantitative structure-activity relationships, allosteric inhibitory site, overview |
|
2.7.12.2 | more |
the MEK enzyme contains a hydrophobic allosteric pocket adjacent to the ATP-binding site which allows for the design of highly selective allosteric inhibitors |
|
2.7.12.2 | more |
design of small molecule MEK1/2 inhibitors to block ERK1/2-mediated signaling and inhibit proliferation. Four structurally distinct MEK1/2 inhibitors acutely affect mitochondrial bioenergetics. The anti-mitochondrial effects of MEK1/2 inhibitors determine the proliferative potential; design of small molecule MEK1/2 inhibitors to block ERK1/2-mediated signaling and inhibit proliferation. Four structurally distinct MEK1/2 inhibitors acutely affect mitochondrial bioenergetics. The anti-mitochondrial effects of MEK1/2 inhibitors determine the proliferative potential |
|